• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

ABPI_Incentivising_Antibioics_peter-pryharski-unsplash_landscape
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Past Event

Can we “Netflix” the Broken Antibiotics Market?

To access the recording please click here.

Type

Sponsored Webinar

Date

01/04/23 03:10 pm
Building on the learnings from the NICE and NHS England pilot with a subscription-style approach to purchasing and evaluating antibiotics.

Antibiotics are the foundation of medicine, but growing antibiotic resistance and a lack of new antibiotics being developed pose a significant threat to society.

Antibiotics are the foundation of medicine, but growing antibiotic resistance poses a significant threat to society. The antibiotics market is broken because companies do not see a return of investment in antibiotics. As a result, there is underinvestment in antibiotic development; no new classes of antibiotics have been discovered since the 1980s and many companies have moved out of the space entirely.

NICE and NHS England took an important first step towards fixing the broken antibiotics market by piloting a Netflix-style model for the evaluation and purchase of antimicrobials. The model, a form of pull-incentive for antibiotics, could increase returns for companies developing antibiotics and stimulate investment in new antibiotics if adopted by enough other countries. The learnings from this pilot are manifold and will shape the future of antimicrobial purchasing and assessment in England and beyond for years to come.

OVERVIEW

In this webinar, OHE’s Lotte Steuten was joined by Nick Crabb (NICE), David Glover (NHS England) and Jason Gordon (HEOR Consulting) to discuss their experience with evaluation and purchasing of antimicrobials and how to build on the learnings from the NICE NHS England AMR pilot:

  • How much should the UK pay for new antibiotics?
  • How should we value new antibiotics?
  • What does the future look like for antibiotic purchasing and evaluation across the world?

SPEAKERS

Dr Nick Crabb, Programme Director, Scientific Affairs, National Institute for Health and Care Excellence (NICE)

Nick had a 20-year career in analytical science, process technology and general management in the chemical, pharmaceutical and contract laboratory industries prior to joining NICE in 2010 to establish and manage the Diagnostics Assessment Programme. Nick currently oversees NICE’s Science Policy and Research programme. Nick has broad scientific and policy interests relating to the evaluation of technologies and interventions to support the development of clinical, public health and social care guidance. His experience includes consideration of HTA issues arising from the availability of novel new products such as cell and gene therapies and work on methods issues relating to the evaluation of antimicrobials. Nick is also the NICE lead on a collaborative project with NHS England to develop and test innovative models for the evaluation and purchase of antimicrobials.

David Glover, Deputy Head of the Medicines Analysis Team at NHS England and Improvement

David Glover became Deputy Head of the Medicines Analysis Team at NHS England and Improvement, in January 2019. Prior to joining the NHS, David worked in central government for over 20 years, including 15 years as an economic adviser to the Department of Health and Social Care and the Office for Life Sciences, having also spent six years as a patent examiner at the UK Intellectual Property Office. He was part of the NICE-NHS England AMR Pilot project team.

Jason Gordon, Chief Commercial Officer and Co-Founder , HEOR

For over 15 years, Jason has shaped health economics and market access strategies and evidence for the world’s leading pharmaceutical and biotechnology companies. Following careers in academia, consultancy, industry and government, Jason has developed his passion for helping companies define the value of new and innovative treatments and form partnerships that optimise patient access and product commercialisation. Jason received his Bachelor of Economics with honours and postgraduate economics training from the University of Adelaide, and a Doctorate in Health Economics from the University of Birmingham.

 

  • Antimicrobial Resistance (AMR)

Related Events

WebsiteImage
  • Past Event
  • Sponsored Webinar
  • March 2023

Informal Caring Burden in HTA Series: Webinar 3 – Capturing carer burden in HTA: what is the future?

Read more
WebsiteImage
  • Past Event
  • Sponsored Webinar
  • February 2023

Informal Caring Burden in HTA Series: Webinar 2 – How is carer burden captured in HTA, and what are some of the existing challenges?

Read more
WebsiteImage
  • Past Event
  • Sponsored Webinar
  • February 2023

Informal Caring Burden in HTA Series: Webinar 1 – What is carer burden and why is it important in HTA?

Read more
ValueofVacc_JoinedImage
  • Past Event
  • OHE Webinar
  • January 2023

The Value of Vaccines and Taskforces

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!